Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5202MR)

This product GTTS-WQ5202MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5202MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12418MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ15950MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ9234MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ7378MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ6633MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ7168MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ8816MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ2538MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW